February 24, 2026 · Phase 2 readout
AZN Phase 2 readout: a positive outcome, +0.4%
On February 24, 2026, AZD5462 — AstraZeneca PLC (Chronic Heart Failure) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +0.4% in the window around the event. It had already run +8.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$204.94
1d before
$206.61
Event day
$205.79
1d after
$203.73
5d after
Pre-catalyst setup
+8.2%
30-day run-up
3780%
30-day volatility
1.3×
volume spike